Gilead pays $43M to license Xilio’s IL-12 program that could turn ‘cold’ tumors ‘hot’

28 Mar 2024
License out/inPhase 1PROTACs
Xilio Therapeutics had a bevy of announcements on Thursday — it entered a licensing deal for its Phase 1 IL-12 program with Gilead, took an investment from private investors, shuffled its pipeline and is laying off 15 employees.
Gilead is placing a $43.5 million bet on Xilio’s engineered interleukin-12, a cytokine that regulates the immune system and could be used to treat cancers. Gilead’s decision to buy into an IL-12 program comes after other Big Pharma companies like AstraZeneca and Bristol Myers Squibb scrapped their IL-12 candidates.
Gilead pays $43M to license Xilio’s IL-12 program that could turn ‘cold’ tumors ‘hot’
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.